ALN-6222 (INHBE) Investigational RNAi therapy targeting inhibin E, undergoing Phase 1 clinical development in adults with obesity as part of Alnylam’s weight-management portfolio.
Visit productCosigns Received
Be the first Cosign
Put your name behind ALN-6222 (INHBE).
Add it to your Products I use list and share why you use it.